The Genedrive PLC (LON: GDR) share price rallied 14.8% after announcing that it was part of a multi-partner team awarded a grant from Innovate UK and the UK government Innovation Accelerator programme.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
The company is part of a team awarded the Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) grant to validate further and implement the new Genedrive® CYP2C19 ID Kit pharmacogenetic test in a time-critical clinical setting.
Top Broker Recommendation
- BlackBull 26,000+ Shares, Options, ETFs, Bonds, and other underlying assets – Read our Review
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- Hargreaves Lansdown The company's website is easily understandable and accessible to a wide range of customers – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
- IG Top-tier regulation – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
The amount awarded is yet to be revealed. Still, Gendrive shall be working in collaboration with the University of Manchester (UoM) in a program that builds on the success of the previous successful UoM/Genedrive partnership with the PALOH programme, which supported the development and evaluation of the Genedrive® MT-RNR1 ID Kit.
The award shall revolve around Genedrive's CYP2C19 ID Kit, one of three exemplar projects to be included in the programme, which is expected to be funded through the Innovate grant, in-kind contributions, and other aligned funding.
The multi-partner grant project shall involve health economists, informaticians, clinicians and researchers to access new technologies and iteratively provide feedback quickly.
The DEVOTE project will focus on patients with ischaemic stroke in acute care who are to be prescribed Clopidogrel to prevent further clot formation. Clopidogrel is typically less effective in patients with specific genetic CYP2C19 variants since they do not effectively metabolise Clopidogrel.
Genedrive's CYP2C19 ID Kit is being developed to guide physicians at the point of care on which patients will respond fully to Clopidogrel. Patients with gene variants that result in reduced or loss of function of CYP2C19 can be given alternative treatments.
David Budd, Genedrive plc’s CEO, said: “DEVOTE is an amazing opportunity to engage formally with a health system like the NHS to demonstrate the effectiveness of a new diagnostic approach. Access to the Acute Medicine Unit in real time has considerable value to Genedrive as further funding would allow us to progress ongoing product development quickly and efficiently and would support the pathway to clinical validation of our Genedrive® CYP2C19 ID Kit.”
*This is not investment advice.
Genedrive share price.
The Genedrive share price rallied 14.78% to trade at 19.80p, from Thursday’s closing price of 17.25p.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
